|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
JPRN |
|
Last refreshed on:
|
17 October 2023 |
|
Main ID: |
JPRN-UMIN000007705 |
|
Date of registration:
|
09/04/2012 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
The effects of AT1 receptor blocker (telmisartan) on serum lipid with hypertensive patients associated with multiple risk factors for cardiovascular disease
|
|
Scientific title:
|
The effects of AT1 receptor blocker (telmisartan) on serum lipid with hypertensive patients associated with multiple risk factors for cardiovascular disease - The effects of telmisartan on serum lipid |
|
Date of first enrolment:
|
2011/09/01 |
|
Target sample size:
|
30 |
|
Recruitment status: |
Recruiting |
|
URL:
|
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009085 |
|
Study type:
|
Interventional |
|
Study design:
|
Single arm Non-randomized
|
|
Phase:
|
Not selected
|
|
|
Countries of recruitment
|
|
Japan
| | | | | | | |
|
Contacts
|
|
Name:
|
minoru takemoto |
|
Address:
|
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan
Japan |
|
Telephone:
|
043-222-7171 |
|
Email:
|
minoru.takemoto@faculty.chiba-u.jp |
|
Affiliation:
|
Chiba University Hospital Department of Medicine, Division of Diabetes, Metabolism and Endocrinology |
|
|
Name:
|
Minoru Takemoto |
|
Address:
|
1-8-1 Inohana, Chuo-ku, Chiba-shi, Chiba 260-8670, Japan
Japan |
|
Telephone:
|
043-222-7171 |
|
Email:
|
minoru.takemoto@faculty.chiba-u.jp |
|
Affiliation:
|
Chiba University Hospital Department of Medicine, Division of Diabetes, Metabolism and Endocrinology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion criteria:
Exclusion criteria: The exclusion criteria were an age >70 years, current history of myocardial infarction and/or cerebral stroke, uncontrollable hypertension (diastolic pressure > 180mmHg) and hyperglycemia (HbA1c > 9.0%), renal failure (serum creatinin > 3.0mg/dL), abnormal liver or muscle enzymes (ALT>100 or ALT>100), patients who applied for other clinical trial within 3 months, expectant mother, lactating woman, patients who had taken ACE-I, thiazolidine and fibrate, inappropriate patients judged by the physician in charge
Age minimum:
20years-old
Age maximum:
70years-old
Gender:
Male and Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Diabetes Mellitus
|
|
Intervention(s)
|
|
Administration of Telmisartan or Telmisartan /Ca antagonist combination drug
|
|
Primary Outcome(s)
|
|
Serum lipid (low density lipoprotein cholesterol)
|
|
Source(s) of Monetary Support
|
|
None
|
|
Ethics review
|
Status: YES
Approval date:
Contact:
|
|
Results
|
|
Results available:
|
Yes |
|
Date Posted:
|
|
|
Date Completed:
|
01/03/2014 |
|
URL:
|
|
|
|